Biomarkers in Multiple Sclerosis: An Up-to-Date Overview
Open Access
- 22 January 2013
- journal article
- review article
- Published by Hindawi Limited in Multiple Sclerosis International
- Vol. 2013, 1-20
- https://doi.org/10.1155/2013/340508
Abstract
During the last decades, the effort of establishing satisfactory biomarkers for multiple sclerosis has been proven to be very difficult, due to the clinical and pathophysiological complexities of the disease. Recent knowledge acquired in the domains of genomics-immunogenetics and neuroimmunology, as well as the evolution in neuroimaging, has provided a whole new list of biomarkers. This variety, though, leads inevitably to confusion in the effort of decision making concerning strategic and individualized therapeutics. In this paper, our primary goal is to provide the reader with a list of the most important characteristics that a biomarker must possess in order to be considered as reliable. Additionally, up-to-date biomarkers are further divided into three subgroups, genetic-immunogenetic, laboratorial, and imaging. The most important representatives of each category are presented in the text and for the first time in a summarizing workable table, in a critical way, estimating their diagnostic potential and their efficacy to correlate with phenotypical expression, neuroinflammation, neurodegeneration, disability, and therapeutical response. Special attention is given to the “gold standards” of each category, like HLA-DRB1* polymorphisms, oligoclonal bands, vitamin D, and conventional and nonconventional imaging techniques. Moreover, not adequately established but quite promising, recently characterized biomarkers, like TOB-1 polymorphisms, are further discussed.Keywords
This publication has 136 references indexed in Scilit:
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisNature, 2011
- Epstein-Barr virus infection of human brain microvessel endothelial cells: A novel role in multiple sclerosisJournal of Neuroimmunology, 2011
- Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple SclerosisNeuropsychopharmacology, 2010
- Translocator Protein PET Imaging for Glial Activation in Multiple SclerosisJournal of Neuroimmune Pharmacology, 2010
- Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple SclerosisArchives of Neurology, 2010
- Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosisNature, 2010
- Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluidAnnals of Neurology, 2009
- Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological eventProceedings of the National Academy of Sciences of the United States of America, 2008
- An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locusProceedings of the National Academy of Sciences of the United States of America, 2007
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006